Canaccord analyst Edward Nash raised the firm’s price target on Travere Therapeutics to $44 from $40 and keeps a Buy rating on the shares. On Friday, Filspari received Accelerated Approval as expected, and there were no surprises on the label, except the increased bar in urine-to-creatinine ratio for the initiation of therapy, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TVTX:
- Travere Therapeutics price target raised to $46 from $42 at Piper Sandler
- Wedbush upgrades Travere Therapeutics to Outperform, raises target to $30
- Travere Therapeutics upgraded to Outperform from Neutral at Wedbush
- Travere Therapeutics price target raised to $40 from $36 at H.C. Wainwright
- Travere Therapeutics price target lowered to $31 from $37 at Barclays
